|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||227.75 - 231.27|
|52 Week Range||162.74 - 250.79|
|PE Ratio (TTM)||21.26|
|Earnings Date||Apr 16, 2018 - Apr 20, 2018|
|Forward Dividend & Yield||3.00 (1.31%)|
|1y Target Est||271.14|
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
Arming teenagers who have Type 1 diabetes with Fitbits, data and weekly emails from physicians can help them better control blood-glucose levels, according results from a recently published study by Minnesota researchers. The findings, published last month in the journal Pediatric Diabetes, could drive a further expansion of such "intensive remote therapy" programs at UnitedHealth Group Inc., which partnered with Minneapolis-based Children’s Minnesota on the study. The idea for the research came from Children’s Minnesota pediatric endocrinologist Dr. Laura Gandrud, who wanted to interact more frequently with patients between visits.
On March 6, 2018, UnitedHealth Group (UNH) reportedly had an interest in the ambulatory services business unit of Envision Healthcare (EVHC) that’s available for sale. The private equity firms led by Carlyle Group (CG) and a consortium of Hellman & Friedman, Onex, and Clayton, Dubilier & Rice are other groups that are interested in Envision Healthcare. No statements have been issued by UnitedHealth Group or Envision.
UnitedHealth Group’s (UNH) quarterly dividends will be paid on March 20, 2018. On February 14, 2018, the company announced the authorization of a quarterly dividend payment of $0.75 per share to shareholders of record on March 9, 2018, payable on March 20, 2018. The dividend amount is the same as previous quarters and reflects an increase of ~20% compared to the quarterly dividend payment of $0.15 per share paid in the previous fiscal year.
On March 13, 2018, UnitedHealth Group (UNH) announced that its vice chair and CEO of Optum, Larry C. Renfro, will now be leading the company’s enterprise growth efforts and Optum Ventures investment funds. He will be succeeded by Andrew Witty, who was recently the CEO of GlaxoSmithKline (GSK). Since August 2017, Witty has been a member of UnitedHealth Group’s board of directors.
The Dow traversed a difficult week, declining over three consecutive trading sessions.
In December 2017, UnitedHealth Group Incorporated (NYSE:UNH) announced its latest earnings update. Overall, analysts seem cautiously optimistic, with profits predicted to increase by 11.12% next year relative to the pastRead More...
Key stock index funds were lower in afternoon trade as Boeing and Johnson & Johnson weighed. Bitcoin and Bitcoin Investment Trust tumbled 9%.
UnitedHealth Group Inc. has dropped out of the sales process for Envision Healthcare Corp. and is no longer interested in a deal for all or part of the medical services company, according to a person familiar ...
A blocked Broadcom/Qualcomm merger and a price target cut for GE triggered some of Tuesday's worst declines.
UnitedHealth Group Inc. said the leader of Optum, its health-services unit, is leaving that role to run its expanding health-services venture-capital arm.
UnitedHealth Group Inc. has named Andrew Witty, the former CEO of GlaxoSmithKline, as the new chief executive of Optum, the insurance giant's fast growing health-services and technology business. Minnetonka-based UnitedHealth (UNH) said in a statement that its current CEO and UnitedHealth vice chair Larry Renfro will stay with the company and lead enterprise growth efforts as well as Optum's growing venture fund operations. Witty is the outgoing Chancellor of the University of Nottingham, a British public research university, and was CEO of pharmaceutical giant GlaxoSmithKline from 2008 until 2017.
Health insurer UnitedHealth Group Inc on Tuesday named its board member and former GlaxoSmithKline Plc head Andrew Witty as chief executive of its pharmacy benefit unit, Optum, effective July 1. Optum's ...
UnitedHealth Group today announced Larry C. Renfro, vice chair of UnitedHealth Group and chief executive officer of Optum, will lead UnitedHealth Group’s enterprise growth efforts and Optum’s next-generation investment initiatives through an expanded Optum Ventures.
Cigna (CI) has projected its expected annual revenue growth rate in the range of 6%–to 8% from 2017 to 2021, assuming the successful completion of its acquisition of Express Scripts. This growth trend is expected to be driven by a robust uptake of Cigna’s current services as well as that of the broad suite of differentiated services that will be added by Express Scripts to Cigna’s portfolio.
Andrew Witty, former chief executive of GlaxoSmithKline, is to join UnitedHealth Group, becoming chief executive of its Optum division, which offers services including pharmacy benefit management to hundreds ...
Cigna (CI) expects the acquisition of Express Scripts to boost the EPS (earnings per share) of the combined company in the double digits in the first full year after the transaction closes. Additionally, Cigna expects to generate higher savings in the long term by integrating medical and pharmacy services as well as other complementary platforms. In 2017, Cigna’s medical cost trend was 3%, while the pharmacy cost trend for Express Scripts was 1.5%.
On March 7, 2018, Cigna (CI) announced that it has entered into a definitive agreement to acquire Express Scripts (ESRX) for a total consideration of $67 billion, which includes $15 billion worth of the latter’s debt. The cash and stock transaction has been structured so every Express Script common share will be purchased for $48.75 in cash and 0.24 of Cigna’s common shares. Cigna has offered Express Scripts’ shareholders a premium of ~31% over Express Scripts’ closing price as of March 7, 2018.